bHypericin, a natural compound from Hypericum perforatum (St. John's wort), has been identified as a specific inhibitor of Leishmania donovani spermidine synthase (LdSS) using integrated computational and biochemical approaches. Hypericin showed in vitro inhibition of recombinant LdSS enzyme activity. The in vivo estimation of spermidine levels in Leishmania promastigotes after hypericin treatment showed significant decreases in the spermidine pools of the parasites, indicating target specificity of the inhibitor molecule. The inhibitor, hypericin, showed significant antileishmanial activity, and the mode of death showed necrosis-like features. Further, decreased trypanothione levels and increased glutathione levels with elevated reactive oxygen species (ROS) levels were observed after hypericin treatment. Supplementation with trypanothione in the medium with hypericin treatment restored in vivo trypanothione levels and ROS levels but could not prevent necrosis-like death of the parasites. However, supplementation with spermidine in the medium with hypericin treatment restored in vivo spermidine levels and parasite death was prevented to a large extent. The data overall suggest that the parasite death due to spermidine starvation as a result of LdSS inhibition is not related to elevated levels of reactive oxygen species. This suggests the involvement of spermidine in processes other than redox metabolism in Leishmania parasites. Moreover, the work provides a novel scaffold, i.e., hypericin, as a potent antileishmanial molecule.
Leishmaniasis is a widespread tropical disease caused by the protozoan parasite Leishmania, which belongs to the order Kinetoplastida and the family Trypanosomatidae. This parasite is transmitted by the vector sandfly, of the genera Phlebotomus and Lutzomyia. There are three forms of clinical manifestations of leishmaniasis, depending on the type of infecting species, namely, cutaneous, mucocutaneous, and visceral leishmaniasis (1). The most deadly form of the disease is visceral leishmaniasis, also known as kala-azar, which is caused mainly by Leishmania donovani in India. According to WHO statistics, 350 million people in 88 countries are at risk of developing the disease. Every year there are 2 million new cases of the disease, of which 0.5 million are cases of visceral leishmaniasis (2, 3). The treatment of leishmaniasis relies mainly on chemotherapy, as there are no vaccines available. Although many drugs are available on the market, they have several limitations (4, 5), indicating a need for novel drug candidates with specific drug targets.All aerobic organisms are exposed to oxidative stress and generate toxic reactive oxygen species (ROS) that can degrade DNA, modify proteins, and adversely affect survival of the organism. The amastigote form of the parasite resides and multiplies inside macrophages, which produce large amounts of hydrogen peroxide. Leishmania parasites are reported to be very sensitive to oxidative stress if the functions of trypanothione metabolism enzymes are d...